HK1005425A1 - Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis - Google Patents

Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis

Info

Publication number
HK1005425A1
HK1005425A1 HK98104564A HK98104564A HK1005425A1 HK 1005425 A1 HK1005425 A1 HK 1005425A1 HK 98104564 A HK98104564 A HK 98104564A HK 98104564 A HK98104564 A HK 98104564A HK 1005425 A1 HK1005425 A1 HK 1005425A1
Authority
HK
Hong Kong
Prior art keywords
dimethoxycinnamoyl
restenosis
medicament
manufacture
treatment
Prior art date
Application number
HK98104564A
Other languages
English (en)
Inventor
Hideo Tamai
Kinzo Ueda
Yung-Sheng Hsu
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of HK1005425A1 publication Critical patent/HK1005425A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK98104564A 1992-09-14 1998-05-27 Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis HK1005425A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4288086A JP2617407B2 (ja) 1992-09-14 1992-09-14 血管内膜細胞過剰増殖疾患の予防および治療剤

Publications (1)

Publication Number Publication Date
HK1005425A1 true HK1005425A1 (en) 1999-01-08

Family

ID=17725612

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98104564A HK1005425A1 (en) 1992-09-14 1998-05-27 Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis

Country Status (7)

Country Link
US (1) US5385935A (ko)
EP (1) EP0588518B1 (ko)
JP (1) JP2617407B2 (ko)
KR (1) KR100252410B1 (ko)
CA (1) CA2106172C (ko)
DE (1) DE69310065T2 (ko)
HK (1) HK1005425A1 (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
CZ258598A3 (cs) 1996-02-15 1998-11-11 Kissei Pharmaceutical Co., Ltd. Inhibitor neovaskularizace
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention
AU739271B2 (en) * 1997-02-14 2001-10-11 Kissei Pharmaceutical Co. Ltd. Agents inhibiting progress of pterygium and postoperative recurrence of the same
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
IL132391A0 (en) * 1997-04-18 2001-03-19 Kissei Pharmaceutical Preventives or remedies for diseases effecting excessive proliferation or retinal pigment eptihelial cells
JP4583597B2 (ja) * 1998-05-05 2010-11-17 ボストン サイエンティフィック リミテッド 末端が滑らかなステント
CA2361581A1 (en) * 1999-02-03 2000-08-10 Smithkline Beecham Corporation Method for the prevention or reduction of cariovascular events associated with coronary intervention
JP2002536326A (ja) * 1999-02-03 2002-10-29 スミスクライン・ビーチャム・コーポレイション 冠状動脈インターベンションに伴う心臓血管事象の予防または軽減方法
ES2250154T3 (es) 1999-07-16 2006-04-16 Kissei Pharmaceutical Co., Ltd. Agentes que inhiben las reacciones de rechazo cronico despues de un transplante de organo.
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
AU2001243248A1 (en) * 2000-02-23 2001-09-03 Smith Kline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
WO2004002367A1 (fr) * 2002-06-27 2004-01-08 Microport Medical (Shanghai) Co., Ltd. Stent eluant des medicaments
US20080306126A1 (en) * 2004-01-05 2008-12-11 Fonseca Vivian A Peroxisome proliferator activated receptor treatment of hyperhomocysteinemia and its complications
US7473738B2 (en) * 2004-09-30 2009-01-06 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
US8668703B2 (en) * 2006-12-01 2014-03-11 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
ES2474765T3 (es) 2009-06-17 2014-07-09 National University Corporation Kumamoto University Agente profiláctico y/o terapéutico para la dismenorrea

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
JPS5640710B2 (ko) * 1973-01-18 1981-09-22
US4337270A (en) * 1980-05-21 1982-06-29 Hisamitsu Pharmaceutical Co., Inc. Novel anthranilic acid derivatives

Also Published As

Publication number Publication date
US5385935A (en) 1995-01-31
JPH06135829A (ja) 1994-05-17
CA2106172A1 (en) 1994-03-15
DE69310065T2 (de) 1997-11-20
EP0588518A1 (en) 1994-03-23
JP2617407B2 (ja) 1997-06-04
KR940006578A (ko) 1994-04-25
EP0588518B1 (en) 1997-04-23
DE69310065D1 (de) 1997-05-28
CA2106172C (en) 2001-01-02
KR100252410B1 (ko) 2000-05-01

Similar Documents

Publication Publication Date Title
HK1005425A1 (en) Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
TW249226B (ko)
EP0686395A3 (en) Use of hyaluronic acid for the manufacture of a medicament for inhibiting the aggregation of platelets
AU7269294A (en) Use of glucokinase inhibitors for the manufacture of a medicament for treating tumours
GR3019760T3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
AU3728095A (en) Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis
HU9700060D0 (en) New compound, it's production and it's use as active component of a medicine
AU9173191A (en) Medicaments for the treatment of papillomavirus diseases
AU2806692A (en) Medicament for the treatment of anxiety
EP0592903A3 (en) Use of Ancrod in the manufacture of medications for the treatment of restenosis.
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
HU9401900D0 (en) A therapeutic process for the treatment of the pathologies of type ii diabetes
AU670491C (en) Pharmaceutical for the treatment of skin disorders
AU8505991A (en) Use of compositions containing 2-(6'-substituted-2'-naphthyl)-acetic acid derivatives for the treatment of respiratory disorders
HUP9904029A3 (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis
AU4081393A (en) Medicaments for the treatment of anxiety
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
IL117465A (en) Use of certain cystine derivatives for the preparation of a medicament for the treatment of restenosis
AU665052B2 (en) The use of a compound for the manufacture of a medicament for the treatment of HIV infection
EG20501A (en) Process for the agrochemical treatment of grasslands
ZA944671B (en) Medicaments for the treatment of inflammatory diseases
EP0622079A3 (en) Gelatinase A for the treatment of Alzheimer's disease.
IL123422A0 (en) Use of 7alpha-methyl-17alpha-ethynyl-estrane derivatives for the manufacture of a medicament for the prophylaxis or the treatment of atherosclerosis

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)